Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: Retrospective cohort study

Leukemia and Lymphoma

Volumn 55, Issue 12, 2014, Pages 2721-2727

  Yamamoto, Wataru ^a   Nakamura, Naoya ^b   Tomita, Naoto ^c   Takeuchi, Kengo ^d   Ishii, Yoshimi ^a   Takahashi, Hiroyuki ^a   Watanabe, Reina ^a   Takasaki, Hirotaka ^a   Motomura, Shigeki ^a   Kobayashi, Shoichi ^a   Yokose, Tomoyuki ^a   Ishigatsubo, Yoshiaki ^c   Sakai, Rika ^a  

^a KANAGAWA CANCER CENTER   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d CANCER INSTITUTE   (Japan)

Author keywords

Diffuse large B cell lymphoma; Flow cytometry; HLA DR; R CHOP therapy; Tumor associated macrophage

Indexed keywords

CD163 ANTIGEN; CHLORDANE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FERRITIN; HLA DR ANTIGEN; LACTATE DEHYDROGENASE; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; TRANSCRIPTION FACTOR PAX5; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; FERRITIN BLOOD LEVEL; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; INTERNATIONAL PROGNOSTIC INDEX; JAPAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; LYMPHOMA CELL; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR ASSOCIATED LEUKOCYTE; CANCER STAGING; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; MACROPHAGE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHENOTYPE; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; MACROPHAGES; MALE; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE;

EID: 84919419837     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.893311     Document Type: Article

References (30)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, IARC Press; 2008. pp 233-237.
2. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
3. Hans CP, Weisenburger DD, Greiner TC, et al. Conformation of the molecular classification of dif use large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275-282.
4. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of dif use large B-cell lymphoma identif ed by gene expression profling. Nature 2000;403:503-511.
5. Beral V, Peterman T, Berkelman R, et al. AIDS-associated non-Hodgkin lymphoma. Lancet 1991;337:805-809.
6. Grivennikov SI, Greten FR, Karin M. Immunity, inf ammation, and cancer. Cell 2010; 140: 883-899.
7. Rimsza LM, Farinha P, Fuchs DA, et al. HLA-DR protein status predicts survival in patients with dif use large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. Leuk Lymphoma 2007;48:542-546.
8. Bernd HW, Ziepert M, Torns C, et al. Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in dif use large B-cell lymphoma-analyses of cases from two prospective randomized clinical trials. Haematologica 2009;94:1569-1580.
9. Rimsza LM, Roberts RA, Miller TP, et al. Loss of MHC class II gene and protein expression in dif use large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004;103:4251-4258.
10. Rimsza LM, Leblanc ML, Unger JM, et al. Gene expression predicts overall survival in paraf n-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008;112:3425-3433.
11. Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 2008;267:204-215.
12. Harris JA, Jain S, Ren Q, et al. CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol 2012;7:12.
13. Greaves P, Clear A, Coutinho R, et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol 2013; 31: 256-262.
14. Sánchez-Espiridión B, Martin-Moreno AM, Montalbán C, et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica 2012; 97: 1080-1084.
15. de Jong D, Koster A, Hagenbeek A, et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specifc treatment protocols. Haematologica 2009;94:70-77.
16. Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, et al. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma 2011; 52:1913-1919.
17. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362: 875-885.
18. Wada N, Zaki MA, Hori Y, et al. Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology 2012; 60: 313-319.
19. Biswas SK, Gangi L, Paul Saki, et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006;107:2112-2122.
20. Niino D, Komohara Y, Murayama T, et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int 2010; 60: 278-283.
21. Carbone PP, Kaplan HS, Musshof K, et al. Report of the committee on Hodgkin's disease staging classifcation. Cancer Res 1971;31:1860-1861.
22. Wilkinson ST, Vanpatten KA, Fernandez DR, et al. Partial plasma cell dif erentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. Blood 2012;119:1459-1467.
23. Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011;117:7070-7078.
24. Ott G, Ziepert M, Klapper W, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classif er predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010;116:4916-4925.
25. Booman M, Douwes J, Glas AM, et al. Mechanisms and effects of loss of human leukocyteantigen class II expression in immune-privileged site-associated B-cell lymphoma. Clin Cancer Res 2006; 12:2698-2705.
26. Riemersma SA, Jordanova ES, Schop RF, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000;96:3569-3577.
27. De Lerma Barbaro A, De Ambrosis A, Banelli B, et al. Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-gamma in promyelocytic cells. Int Immunol 2008;20:1457-1466.
28. Cycon KA, Mulvaney K, Rimsza LM, et al. Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma. Immunology 2013; 140: 259-272.
29. Rosário C, Zandman-Goddard G, Meyron-Holtz EG, et al. The hyperferritinemic syndrome macrophage: activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med 2013;11:185.
30. Yoh KA, Lee HS, Park LC, et al. The prognostic significance of elevated levels of serum ferritin before chemotherapy in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2014; 14:43-49.